Kelman Lazarov, Inc. Amgen Inc Transaction History

Kelman Lazarov, Inc.

$525 Million
Q3 2024

A detailed history of Kelman Lazarov, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Kelman Lazarov, Inc. holds 678 shares of AMGN stock, worth $199,691. This represents 0.04% of its overall portfolio holdings.

Number of Shares

678

Previous 724 6.35%

Holding current value

$199,691

Previous $226,000 3.54%

% of portfolio

0.04%

Previous 0.05%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$309.38 - $337.38 $14,231 - $15,519	-46 Reduced 6.35%	678 $218,000
Q2 2024 Aug 12, 2024	SELL	$262.75 - $319.31 $2,627 - $3,193	-10 Reduced 1.36%	724 $226,000
Q1 2024 May 09, 2024	BUY	$268.87 - $324.56 $2,688 - $3,245	10 Added 1.38%	734 $208,000
Q4 2023 Feb 01, 2024	BUY	$255.7 - $288.46 $185,126 - $208,845	724 New	724 $208,000
Q3 2021 Nov 04, 2021	SELL	$212.27 - $248.7 $187,222 - $219,353	-882 Closed	0 $0
Q2 2020 Jul 29, 2020	SELL	$197.81 - $242.74 $97,520 - $119,670	-493 Reduced 35.85%	882 $208,000
Q1 2020 Apr 27, 2020	SELL	$182.24 - $241.7 $26,607 - $35,288	-146 Reduced 9.6%	1,375 $279,000
Q3 2019 Oct 15, 2019	SELL	$174.11 - $208.62 $6,267 - $7,510	-36 Reduced 2.31%	1,521 $294,000
Q1 2019 May 08, 2019	BUY	$180.87 - $203.88 $83,200 - $93,784	460 Added 41.93%	1,557 $296,000
Q4 2018 Feb 11, 2019	SELL	$178.4 - $208.25 $55,660 - $64,974	-312 Reduced 22.14%	1,097 $214,000
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $9,449 - $10,653	-51 Reduced 3.49%	1,409 $292,000
Q2 2018 Aug 03, 2018	SELL	$166.05 - $186.51 $19,926 - $22,381	-120 Reduced 7.59%	1,460 $270,000
Q3 2017 Oct 05, 2017	BUY	$167.29 - $191.0 $264,318 - $301,780	1,580	1,580 $295,000

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kelman Lazarov, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kelman Lazarov, Inc. with notifications on news.

Account

Kelman Lazarov, Inc. Amgen Inc Transaction History